Lazard Asset Management LLC Purchases 74,799 Shares of Core Laboratories N.V. (CLB)

Lazard Asset Management LLC raised its stake in shares of Core Laboratories N.V. (NYSE:CLB) by 43.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 245,345 shares of the oil and gas company’s stock after buying an additional 74,799 shares during the period. Lazard Asset Management LLC owned approximately 0.56% of Core Laboratories N.V. worth $28,342,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Asset Management One Co. Ltd. increased its stake in shares of Core Laboratories N.V. by 180.1% in the fourth quarter. Asset Management One Co. Ltd. now owns 107,664 shares of the oil and gas company’s stock valued at $12,889,000 after buying an additional 69,221 shares during the period. Aviva PLC increased its stake in shares of Core Laboratories N.V. by 7.1% in the fourth quarter. Aviva PLC now owns 29,078 shares of the oil and gas company’s stock valued at $3,490,000 after buying an additional 1,915 shares during the period. Elkfork Partners LLC acquired a new stake in shares of Core Laboratories N.V. during the fourth quarter valued at about $1,415,000. Precocity Capital LP acquired a new stake in shares of Core Laboratories N.V. during the fourth quarter valued at about $6,002,000. Finally, Archon Capital Management LLC increased its stake in shares of Core Laboratories N.V. by 10.0% in the fourth quarter. Archon Capital Management LLC now owns 27,070 shares of the oil and gas company’s stock valued at $3,249,000 after buying an additional 2,470 shares during the period.

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Shares of Core Laboratories N.V. (NYSE CLB) traded down 1.99% during trading on Tuesday, reaching $104.38. 409,753 shares of the company traded hands. The firm has a market capitalization of $4.61 billion, a PE ratio of 69.13 and a beta of 1.51. Core Laboratories N.V. has a 12 month low of $96.30 and a 12 month high of $127.82. The firm has a 50-day moving average price of $106.26 and a 200-day moving average price of $113.82.

Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings results on Wednesday, April 19th. The oil and gas company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.39 by $0.03. The business had revenue of $157.81 million for the quarter, compared to the consensus estimate of $150.44 million. Core Laboratories N.V. had a net margin of 11.10% and a return on equity of 43.28%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.37 EPS. Equities research analysts anticipate that Core Laboratories N.V. will post $2.21 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, May 23rd. Investors of record on Friday, April 28th were given a dividend of $0.55 per share. The ex-dividend date was Thursday, April 27th. This represents a $2.20 annualized dividend and a yield of 2.11%. Core Laboratories N.V.’s dividend payout ratio (DPR) is 145.70%.

ILLEGAL ACTIVITY NOTICE: This report was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://sportsperspectives.com/2017/06/20/lazard-asset-management-llc-has-28-34-million-stake-in-core-laboratories-n-v-clb-updated.html.

Several analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a report on Tuesday, April 11th. ABN Amro raised shares of Core Laboratories N.V. to a “hold” rating in a research note on Friday, April 21st. Loop Capital raised shares of Core Laboratories N.V. from a “hold” rating to a “buy” rating and upped their price objective for the company from $125.00 to $130.00 in a research note on Friday, April 21st. Scotiabank set a $136.00 price objective on shares of Core Laboratories N.V. and gave the company a “hold” rating in a research note on Saturday, April 22nd. Finally, Citigroup Inc. reissued a “neutral” rating and set a $117.00 price objective (down previously from $119.00) on shares of Core Laboratories N.V. in a research note on Saturday, March 11th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. Core Laboratories N.V. currently has a consensus rating of “Hold” and a consensus price target of $121.22.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply